At a glance
- Originator Bristol-Myers Squibb
- Class Anti-ischaemics; Benzopyrans; Cardiotonics; Guanidines; Ischaemic heart disorder therapies; Vasodilators
- Mechanism of Action KATP channel stimulants; Potassium channel agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Myocardial ischaemia